blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3484463

EP3484463 - SELECTIVE ESTROGEN-RECEPTOR MODULATORS (SERMS) CONFER PROTECTION AGAINST PHOTORECEPTOR DEGENERATION [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  18.12.2020
Database last updated on 14.03.2026
FormerThe patent has been granted
Status updated on  10.01.2020
FormerGrant of patent is intended
Status updated on  29.10.2019
FormerRequest for examination was made
Status updated on  11.10.2019
FormerGrant of patent is intended
Status updated on  02.07.2019
FormerRequest for examination was made
Status updated on  19.04.2019
FormerThe international publication has been made
Status updated on  24.02.2018
Formerunknown
Status updated on  05.09.2017
Most recent event   Tooltip15.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 17.08.2022  [2022/33]
Applicant(s)For all designated states
The United States of America, as Represented by The Secretary, Department of Health and Human Services Office of Technology, Transfer
National Institute of Health
6011 Executive Boulevard
Suite 325
MSC 7660
Bethesda, MD 20892-7660 / US
[N/P]
Former [2019/21]For all designated states
The United States of America, as Represented by The Secretary, Department of Health and Human Services Office of Technology Tr
National Institute of Health
6011 Executive Boulevard
Suite 325
MSC 7660
Bethesda, MD 20892-7660 / US
Inventor(s)01 / MA, Wenxin
6 Center Drive
6/215 National Eye Institute
Bethesda MD 20892 / US
02 / ZHAO, Lian
6 Center Drive
6/215 National Eye Institute
Bethesda MD 20892 / US
03 / WANG, Xu
6 Center Drive
6/215 National Eye Institute
Bethesda MD 20892 / US
04 / WONG, Wai, T.
6 Center Drive
6/217 National Eye Institute
Bethesda MD 20892 / US
 [2019/21]
Representative(s)Forresters IP LLP
Skygarden
Erika-Mann-Straße 11
80636 München / DE
[N/P]
Former [2019/21]Gowshall, Jonathan Vallance
Forresters IP LLP
Skygarden
Erika-Mann-Strasse 11
80636 München / DE
Application number, filing date17757972.910.08.2017
[2019/21]
WO2017US46359
Priority number, dateUS201662377439P19.08.2016         Original published format: US 201662377439 P
[2019/21]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2018034945
Date:22.02.2018
Language:EN
[2018/08]
Type: A1 Application with search report 
No.:EP3484463
Date:22.05.2019
Language:EN
The application published by WIPO in one of the EPO official languages on 22.02.2018 takes the place of the publication of the European patent application.
[2019/21]
Type: B1 Patent specification 
No.:EP3484463
Date:12.02.2020
Language:EN
[2020/07]
Search report(s)International search report - published on:EP22.02.2018
ClassificationIPC:A61K31/138, A61K31/4535, A61K31/55, A61P27/02
[2019/21]
CPC:
A61K31/138 (EP,US); A61B5/398 (US); A61B5/4848 (US);
A61K31/4535 (EP,US); A61K31/55 (EP,US); A61P27/02 (EP,US)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/21]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:SELEKTIVE ÖSTROGENREZEPTORMODULATOREN (SERM) ZUR VERLEIHUNG VON SCHUTZ GEGEN PHOTOREZEPTORDEGENERATION[2019/21]
English:SELECTIVE ESTROGEN-RECEPTOR MODULATORS (SERMS) CONFER PROTECTION AGAINST PHOTORECEPTOR DEGENERATION[2019/21]
French:MODULATEURS SÉLECTIFS DU RÉCEPTEUR DES OESTROGÈNES (SERMS) CONFÉRANT UNE PROTECTION CONTRE LA DÉGÉNÉRESCENCE DES PHOTORÉCEPTEURS[2019/21]
Entry into regional phase13.02.2019National basic fee paid 
13.02.2019Designation fee(s) paid 
13.02.2019Examination fee paid 
Examination procedure13.02.2019Amendment by applicant (claims and/or description)
13.02.2019Examination requested  [2019/21]
13.02.2019Date on which the examining division has become responsible
03.07.2019Communication of intention to grant the patent
10.10.2019Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
10.10.2019Fee for grant paid
10.10.2019Fee for publishing/printing paid
07.11.2019Communication of intention to grant the patent
02.01.2020Receipt of the translation of the claim(s)
Opposition(s)13.11.2020No opposition filed within time limit [2021/03]
Fees paidRenewal fee
27.08.2019Renewal fee patent year 03
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU10.08.2017
AL12.02.2020
AT12.02.2020
CY12.02.2020
CZ12.02.2020
DK12.02.2020
EE12.02.2020
ES12.02.2020
FI12.02.2020
HR12.02.2020
IT12.02.2020
LT12.02.2020
LV12.02.2020
MC12.02.2020
MK12.02.2020
MT12.02.2020
NL12.02.2020
PL12.02.2020
RO12.02.2020
RS12.02.2020
SE12.02.2020
SI12.02.2020
SK12.02.2020
SM12.02.2020
TR12.02.2020
BG12.05.2020
NO12.05.2020
GR13.05.2020
IS12.06.2020
PT05.07.2020
IE10.08.2020
LU10.08.2020
BE31.08.2020
[2022/31]
Former [2022/30]HU10.08.2017
AL12.02.2020
AT12.02.2020
CY12.02.2020
CZ12.02.2020
DK12.02.2020
EE12.02.2020
ES12.02.2020
FI12.02.2020
HR12.02.2020
IT12.02.2020
LT12.02.2020
LV12.02.2020
MC12.02.2020
MT12.02.2020
NL12.02.2020
PL12.02.2020
RO12.02.2020
RS12.02.2020
SE12.02.2020
SI12.02.2020
SK12.02.2020
SM12.02.2020
TR12.02.2020
BG12.05.2020
NO12.05.2020
GR13.05.2020
IS12.06.2020
PT05.07.2020
IE10.08.2020
LU10.08.2020
BE31.08.2020
Former [2022/27]HU10.08.2017
AT12.02.2020
CY12.02.2020
CZ12.02.2020
DK12.02.2020
EE12.02.2020
ES12.02.2020
FI12.02.2020
HR12.02.2020
IT12.02.2020
LT12.02.2020
LV12.02.2020
MC12.02.2020
MT12.02.2020
NL12.02.2020
PL12.02.2020
RO12.02.2020
RS12.02.2020
SE12.02.2020
SI12.02.2020
SK12.02.2020
SM12.02.2020
TR12.02.2020
BG12.05.2020
NO12.05.2020
GR13.05.2020
IS12.06.2020
PT05.07.2020
IE10.08.2020
LU10.08.2020
BE31.08.2020
Former [2021/37]AT12.02.2020
CZ12.02.2020
DK12.02.2020
EE12.02.2020
ES12.02.2020
FI12.02.2020
HR12.02.2020
IT12.02.2020
LT12.02.2020
LV12.02.2020
MC12.02.2020
NL12.02.2020
PL12.02.2020
RO12.02.2020
RS12.02.2020
SE12.02.2020
SI12.02.2020
SK12.02.2020
SM12.02.2020
BG12.05.2020
NO12.05.2020
GR13.05.2020
IS12.06.2020
PT05.07.2020
IE10.08.2020
LU10.08.2020
BE31.08.2020
Former [2021/36]AT12.02.2020
CZ12.02.2020
DK12.02.2020
EE12.02.2020
ES12.02.2020
FI12.02.2020
HR12.02.2020
IT12.02.2020
LT12.02.2020
LV12.02.2020
MC12.02.2020
NL12.02.2020
PL12.02.2020
RO12.02.2020
RS12.02.2020
SE12.02.2020
SI12.02.2020
SK12.02.2020
SM12.02.2020
BG12.05.2020
NO12.05.2020
GR13.05.2020
IS12.06.2020
PT05.07.2020
LU10.08.2020
BE31.08.2020
Former [2021/20]AT12.02.2020
CZ12.02.2020
DK12.02.2020
EE12.02.2020
ES12.02.2020
FI12.02.2020
HR12.02.2020
IT12.02.2020
LT12.02.2020
LV12.02.2020
MC12.02.2020
NL12.02.2020
PL12.02.2020
RO12.02.2020
RS12.02.2020
SE12.02.2020
SI12.02.2020
SK12.02.2020
SM12.02.2020
BG12.05.2020
NO12.05.2020
GR13.05.2020
IS12.06.2020
PT05.07.2020
LU10.08.2020
Former [2021/18]AT12.02.2020
CZ12.02.2020
DK12.02.2020
EE12.02.2020
ES12.02.2020
FI12.02.2020
HR12.02.2020
IT12.02.2020
LT12.02.2020
LV12.02.2020
MC12.02.2020
NL12.02.2020
PL12.02.2020
RO12.02.2020
RS12.02.2020
SE12.02.2020
SI12.02.2020
SK12.02.2020
SM12.02.2020
BG12.05.2020
NO12.05.2020
GR13.05.2020
IS12.06.2020
PT05.07.2020
Former [2021/10]AT12.02.2020
CZ12.02.2020
DK12.02.2020
EE12.02.2020
ES12.02.2020
FI12.02.2020
HR12.02.2020
IT12.02.2020
LT12.02.2020
LV12.02.2020
NL12.02.2020
PL12.02.2020
RO12.02.2020
RS12.02.2020
SE12.02.2020
SI12.02.2020
SK12.02.2020
SM12.02.2020
BG12.05.2020
NO12.05.2020
GR13.05.2020
IS12.06.2020
PT05.07.2020
Former [2020/50]CZ12.02.2020
DK12.02.2020
EE12.02.2020
ES12.02.2020
FI12.02.2020
HR12.02.2020
LT12.02.2020
LV12.02.2020
NL12.02.2020
RO12.02.2020
RS12.02.2020
SE12.02.2020
SK12.02.2020
SM12.02.2020
BG12.05.2020
NO12.05.2020
GR13.05.2020
IS12.06.2020
PT05.07.2020
Former [2020/49]CZ12.02.2020
DK12.02.2020
ES12.02.2020
FI12.02.2020
HR12.02.2020
LT12.02.2020
LV12.02.2020
NL12.02.2020
RO12.02.2020
RS12.02.2020
SE12.02.2020
SK12.02.2020
SM12.02.2020
BG12.05.2020
NO12.05.2020
GR13.05.2020
IS12.06.2020
PT05.07.2020
Former [2020/48]DK12.02.2020
ES12.02.2020
FI12.02.2020
HR12.02.2020
LT12.02.2020
LV12.02.2020
NL12.02.2020
RO12.02.2020
RS12.02.2020
SE12.02.2020
SM12.02.2020
BG12.05.2020
NO12.05.2020
GR13.05.2020
IS12.06.2020
PT05.07.2020
Former [2020/47]DK12.02.2020
ES12.02.2020
FI12.02.2020
HR12.02.2020
LT12.02.2020
LV12.02.2020
NL12.02.2020
RS12.02.2020
SE12.02.2020
BG12.05.2020
NO12.05.2020
GR13.05.2020
IS12.06.2020
Former [2020/45]FI12.02.2020
HR12.02.2020
LV12.02.2020
NL12.02.2020
RS12.02.2020
SE12.02.2020
BG12.05.2020
NO12.05.2020
GR13.05.2020
IS12.06.2020
Former [2020/40]FI12.02.2020
HR12.02.2020
LV12.02.2020
RS12.02.2020
SE12.02.2020
BG12.05.2020
NO12.05.2020
GR13.05.2020
IS12.06.2020
Former [2020/39]FI12.02.2020
HR12.02.2020
LV12.02.2020
RS12.02.2020
SE12.02.2020
BG12.05.2020
NO12.05.2020
GR13.05.2020
Former [2020/38]FI12.02.2020
HR12.02.2020
LV12.02.2020
RS12.02.2020
SE12.02.2020
NO12.05.2020
GR13.05.2020
Former [2020/37]FI12.02.2020
HR12.02.2020
LV12.02.2020
RS12.02.2020
SE12.02.2020
NO12.05.2020
Former [2020/35]FI12.02.2020
NO12.05.2020
Cited inInternational search[A] WO0234266  (LILLY CO ELI et al.)
 [A] US2013338145  (MITCHELL CLAIRE H et al.)
 [XP]   XU WANG ET AL: "Tamoxifen Provides Structural and Functional Rescue in Murine Models of Photoreceptor Degeneration", JOURNAL OF NEUROSCIENCE, vol. 37, no. 12, 24 February 2017 (2017-02-24), US, pages 3294 - 3310, XP055417460, ISSN: 0270-6474, DOI: 10.1523/JNEUROSCI.2717-16.2017

DOI:   http://dx.doi.org/10.1523/JNEUROSCI.2717-16.2017
 [A]   XU WANG: "Requirement for microglia for the maintenance of synaptic function and integrity in the mature retina", THE JOURNAL OF NEUROSCIENCE, 2 March 2016 (2016-03-02), pages 2827 - 2842, XP055417473, Retrieved from the Internet [retrieved on 20171019]

DOI:   http://dx.doi.org/10.1523/JNEUROSCI.3575-15.2016
 [A]   JIN NI ET AL: "Friend or Foe? Resident Microglia vs Bone Marrow-Derived Microglia and Their Roles in the Retinal Degeneration", MOLECULAR NEUROBIOLOGY, HUMANA PRESS, US, vol. 54, no. 6, 18 June 2016 (2016-06-18), pages 4094 - 4112, XP036276809, ISSN: 0893-7648, [retrieved on 20160618], DOI: 10.1007/S12035-016-9960-9

DOI:   http://dx.doi.org/10.1007/s12035-016-9960-9
by applicantUS4536516
 US2003158160
 US2016075726
 US2006105041
 US2004138314
 US5219549
 US4919937
 US7485623
 US2012219528
 US5869079
 US6699493
 US5443505
 US5766242
 US0000207
 US0214279
 US6251090
 US6299895
 US6416777
 US6413540
 US0028187
   CONGDON ET AL., ARCHIVES OF OPHTHALMOLOGY, vol. 122, 2004, pages 477 - 448
   JONAS ET AL., AMERICAN JOURNAL OF OPHTHALMOLOGY, vol. 158, 2014, pages 808 - 815
   HOLZ ET AL., OPHTHALMOLOGY, vol. 121, 2014, pages 1079 - 1091
   WERT ET AL., DEVELOPMENTS IN OPHTHALMOLOGY, vol. 53, 2014, pages 33 - 43
   YOSHIDA ET AL., OPHTHALMOLOGY, vol. 120, 2013, pages 100 - 105
   YOSHIDA ET AL., OPHTHALMOLOGY, vol. 120, 2013, pages e5 - e12
   ROQUE ET AL., INVEST OPHTHALMOL VIS SCI, vol. 37, 1996, pages 196 - 203
   GUPTA ET AL., EXP EYE RES, vol. 76, 2003, pages 463 - 471
   ZHAO ET AL., EMBO MOLECULAR MEDICINE, vol. 7, 2015, pages 1179 - 1197
   ZABEL ET AL., GLIA, vol. 64, 2016, pages 1479 - 1491
   PENG ET AL., THE JOURNAL OF NEUROSCIENCE : THE OFFICIAL JOURNAL OF THE SOCIETY FOR NEUROSCIENCE, vol. 34, 2014, pages 8139 - 8150
   SCHOLZ ET AL., JOURNAL OF NEUROINFLAMMATION, vol. 12, 2015, pages 209
   EVANS J; WORMALD R., BRITISH JOURNAL OPHTHALMOLOGY, vol. 80, 1996, pages 9 - 14
   KLEIN R; KLEIN B E K; LINTON K L P, OPHTHALMOLOGY, vol. 99, 1992, pages 933 - 943
   VINGERLING J R, OPHTHALMOLOGY, vol. 102, 1995, pages 205 - 210
   HAGEMAN G S; MULLINS R F, MOL VIS, vol. 5, 1999, pages 28
   PHYSIOL REV, vol. 76, 1996, pages 69 - 125
   E. W. MARTIN: "Remington's Pharmaceutical Sciences", 1975, MACK PUBLISHING CO.
   PURR; JORDAN, PHARMACOLOGY AND THERAPEUTICS, vol. 25, 1984, pages 127 - 205
   POWLES, T. J., NAT REV CANCER, vol. 2, 2002, pages 787 - 794
   JORDAN, V. C., NAT REV DRUG DISCOV, vol. 2, 2003, pages 205 - 213
   KASTRATI ET AL., PLOS ONE, vol. 6, no. 11, 2011, pages e27876
   AMBATI ET AL., INVEST. OPTHALMOL. VIS. SCI., vol. 41, 2000, pages 1181 - 1185
   AMBATI ET AL., INVEST. OPTHALMOL. VIS. SCI., vol. 41, 2000, pages 1186 - 1191
   KRETSCHMER ET AL., JOURNAL OF NEUROSCIENCE METHODS, 2015
   MA ET AL., NEUROBIOLOGY OF AGING, vol. 34, 2013, pages 943 - 960
   PENNESI ET AL., INVEST OPHTHALMOL VIS SCI, vol. 53, 2012, pages 4644 - 4656
   CHANG ET AL., VISION RESEARCH, vol. 47, 2007, pages 624 - 633
   MCLAUGHLIN ET AL., NATURE GENETICS, vol. 4, 1993, pages 130 - 134
   RIGGS; HARTMANN, THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 348, 2003, pages 618 - 629
   ISMAILOGLU ET AL., OFFICIAL JOURNAL OF THE NEUROSURGICAL SOCIETY OF AUSTRALASIA, vol. 17, 2010, pages 1306 - 1310
   TORRE VALDOVINOS ET AL., JOURNAL OF VETERINARY MEDICINE, vol. 2016, 2016, pages 9561968
   AREVALO ET AL., JOURNAL OF NEUROENDOCRINOLOGY, vol. 24, 2012, pages 183 - 190
   FRANCO RODRIGUEZ ET AL., BRAIN RESEARCH BULLETIN, vol. 98, 2013, pages 64 - 75
   BARRETO ET AL., FRONTIERS IN AGING NNEUROSCIENCE, vol. 6, 2014, pages 132
   LIU ET AL., BRAIN RESEARCH, vol. 1316, 2010, pages 101 - 111
   NAYFIELD; GORIN, JOURNAL OF CLINICAL ONCOLOGY : OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY, vol. 14, 1996, pages 1018 - 1026
   GUALINO ET AL., AMERICAN JOURNAL OF OPHTHALMOLOGY, vol. 140, 2005, pages 757 - 758
   BOURLA ET AL., AMERICAN JOURNAL OF OPHTHALMOLOGY, vol. 144, 2007, pages 126 - 128
   GORIN ET AL., AMERICAN JOURNAL OF OPHTHALMOLOGY, vol. 125, 1998, pages 493 - 501
   SALOMAO ET AL., CURRENT EYE RESEARCH, vol. 32, 2007, pages 345 - 352
   WATANABE ET AL., DOCUMENTA OPHTHALMOLOGICA ADVANCES IN OPHTHALMOLOGY, vol. 120, 2010, pages 137 - 143
   CHO ET AL., INVEST OPHTHALMOL VIS SCI, vol. 53, 2012, pages 5344 - 5353
   KIM ET AL., INVEST OPHTHALMOL VIS SCI, vol. 55, 2014, pages 4747 - 4758
   WANG ET AL., THE JOURNAL OF NEUROSCIENCE : THE OFFICIAL JOURNAL OF THE SOCIETY FOR NEUROSCIENCE, vol. 36, 2016, pages 2827 - 2842
   HAYASHI; MCMAHON, DEVELOPMENTAL BIOLOGY, vol. 244, 2002, pages 305 - 318
   BONEVA ET AL., NEUROSCIENCE, vol. 325, 2016, pages 188 - 201
   ELZER ET AL., JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM : OFFICIAL JOURNAL OF THE INTERNATIONAL SOCIETY OF CEREBRAL BLOOD FLOW AND METABOLISM, vol. 30, 2010, pages 935 - 942
   ZHANG ET AL., EXPERIMENTAL NEUROLOGY, vol. 204, 2007, pages 819 - 827
   OGUETA ET AL., INVEST OPHTHALMOL VIS SCI, vol. 40, 1999, pages 1906 - 1911
   CASCIO ET AL., EXP EYE RES, vol. 85, 2007, pages 166 - 172
   LI ET AL., HUMAN MOLECULAR GENETICS, vol. 24, 2015, pages 4417 - 4428
   FEIL ET AL., BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 237, 1997, pages 752 - 757
   GOLDMANN ET AL., NATURE NEUROSCIENCE, vol. 16, 2013, pages 1618 - 1626
   PARKHURST ET AL., CELL, vol. 155, 2013, pages 1596 - 1609
   YONA ET AL., IMMUNITY, vol. 38, 2013, pages 79 - 91
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.